Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

330
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
330
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

4.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.8K
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

598
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
598
Esophageal Perforation-II: Clinical Manifestations and Management01:28

Esophageal Perforation-II: Clinical Manifestations and Management

737
Esophageal perforations manifest in various clinical forms, influenced by factors such as the perforation's cause and location (cervical, intrathoracic, or intra-abdominal), the extent of contamination, and potential injury to adjacent mediastinal structures. The timing between the perforation occurrence and treatment initiation also affects the clinical presentation.
Clinical Manifestations:
737
Barrett Esophagus-II: Clinical Manifestations and Management01:21

Barrett Esophagus-II: Clinical Manifestations and Management

1.1K
Individuals with Barrett's esophagus are often asymptomatic, but they may experience symptoms commonly associated with GERD, such as heartburn and acid regurgitation. Additional symptoms can include difficulty swallowing, chest pain, unintentional weight loss, blood in the stool (which may appear black, tarry, or bloody), and episodes of vomiting.
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
1.1K
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

588
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
588

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Crizotinib or vebreltinib response and resistance in advanced non-small cell lung cancer with MET exon 14 skipping.

Discover oncology·2026
Same author

Exploratory Identification of Gene Copy Number Cut-Off for NGS-Based <i>MET</i> Amplification Assessment and Clinical Relevance to MET Inhibitor Outcomes in Non-Small-Cell Lung Cancer.

Lung Cancer (Auckland, N.Z.)·2026
Same author

Abnormal cortical hierarchy revealed by gradient dysfunction in patients with definite amyotrophic lateral sclerosis.

Brain research bulletin·2026
Same author

Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial.

Nature medicine·2026
Same author

Impairment of brain short association fibers across clinical stages in amyotrophic lateral sclerosis: a new biomarker mirroring disease progression.

BMC medicine·2026
Same author

Osimertinib with or without savolitinib as first-line treatment for MET-aberrant, EGFR-mutant NSCLC: randomized phase 2 trial (FLOWERS).

Nature communications·2026

相关实验视频

Updated: Feb 6, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

416

临床进展模式的crizotinib失败和后续管理的先进的非小细胞肺癌与ROS1重新安排.

Quan-Quan Tan1, Yu-Qing Chen2, Yu-Er Gao3

  • 1Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), southern Medical University, Guangzhou, China.

Cancer medicine
|February 4, 2026
PubMed
概括

在ROS1重组NSCLC治疗crizotinib后的进展模式显著影响存活率. 了解这些模式,例如剧烈与渐进/局部进展,可以指导未来的治疗决策.

关键词:
在NSCLCLC中,我们可以看到.在ROS1上,它是ROS1的.临床进展模式幸存的好处是生存的好处.

更多相关视频

Author Spotlight: Establishing a Murine Non-Small Cell Lung Cancer Model for Developing Nanoformulations of Anticancer Drugs
05:11

Author Spotlight: Establishing a Murine Non-Small Cell Lung Cancer Model for Developing Nanoformulations of Anticancer Drugs

Published on: May 10, 2024

1.9K
Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer
06:49

Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer

Published on: February 10, 2023

2.8K

相关实验视频

Last Updated: Feb 6, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

416
Author Spotlight: Establishing a Murine Non-Small Cell Lung Cancer Model for Developing Nanoformulations of Anticancer Drugs
05:11

Author Spotlight: Establishing a Murine Non-Small Cell Lung Cancer Model for Developing Nanoformulations of Anticancer Drugs

Published on: May 10, 2024

1.9K
Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer
06:49

Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer

Published on: February 10, 2023

2.8K

科学领域:

  • 在瘤学瘤学.
  • 医学遗传学 医学遗传学
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 克里佐替尼 (crizotinib) 是ROS1重组非小细胞肺癌 (NSCLC) 的标准一线治疗方法.
  • 有限的数据存在临床进展模式和随后的治疗策略后crizotinib失败在这个患者群体.

研究的目的:

  • 在crizotinib治疗后分析ROS1重组NSCLC患者的临床进展模式.
  • 调查与不同进展模式相关的生存结果和潜在抵抗机制.
  • 根据进展模式为后续治疗策略提供信息.

主要方法:

  • 二十八名患有ROS1重组NSCLC的患者被追溯分析.
  • 根据临床数据,患者被分为剧烈或渐进/局部进展组.
  • 评估了临床特征,生存结果 (无进展生存,总生存) 和耐药性机制.

主要成果:

  • 与渐进/局部进展 (分别为22.0个月和90.3个月) 相比,剧烈进展显示中位数无进展生存时间 (8.0个月) 和总生存时间 (14.2个月) 显著较短.
  • 在剧烈的进展中,随后的治疗在有效性上有所不同,在化学疗法,向治疗和最佳支持性护理中,在进展后的生存率和整体生存率上存在显著差异.
  • 在剧烈的进展中,ROS1激酶域突变普遍存在,而绕道和下游通路激活的特征是渐进/局部进展.

结论:

  • 在crizotinib治疗后,ROS1-重组NSCLC的进展模式预测了生存结果.
  • 识别进展模式可以帮助量身定制后续治疗策略,以改善患者管理.